We found both the CRS + 10 mg/kg HE and CRS + 25 mg/kg HE treatment groups exhibited significantly increased neuroplasticity- and neurogenesis-related gene expressions, including Bdnf, Syp, Nestin, and Psd-95. The gene discussed is DLG4; the disease is congenital rubella syndrome.